ramucirumab
Trade name: cyramza
mAbapprovedOrphan Drug FDAFast Track FDA
Approved
Apr 21, 2014
Ramucirumab, sold under the brand name Cyramza, is a fully human monoclonal antibody (IgG1) used for the treatment of cancer. Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist. Ramucirumab was developed by ImClone Systems. — Wikipedia
Clinical trial activity
159 trials · 100 clinical orgs · 1 marketing orgs
Phase 1
50
Phase 2
120
Phase 3
23
Phase 4
1
Earliest trial started Jan 1, 2005 (NCT00793975)
Timeline
2000s
Indications
Approved for
Studied for
- Adenocarcinoma · Phase 3
- Adolescent · Phase 2
- Bile Duct Neoplasms · Phase 2
- Biliary Tract Neoplasms · Phase 2
- Breast Neoplasms · Phase 3
- Carcinoid Tumor · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Ovarian Epithelial · Phase 1
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 3
- Child · Phase 2
- Cholangiocarcinoma · Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 3
- Desmoplastic Small Round Cell Tumor · Phase 1/Phase 2
- Drug Therapy · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 3
- Esophagogastric Junction · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Gallbladder Neoplasms · Phase 2
- Glioblastoma · Phase 2
- Hamartoma · Phase 2
- Healthy Volunteers · Phase 1
- Intestinal Neoplasms · Phase 2
- Liver Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 3
- Lymphoma, Mantle-Cell · Phase 1
- Melanoma · Phase 2
- Mesothelioma · Phase 2
- Mesothelioma, Malignant · Phase 2
- Mutation · Phase 2
- Neoplasm Metastasis · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Rectal Neoplasms · Phase 2
- Sarcoma, Synovial · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 4
- Thymoma · Phase 2
- Ureteral Neoplasms · Phase 2
- Urethral Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
Approval history
- approvedFast trackApr 21, 2014
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaRamucirumab ↗
- NCATSD99YVK4L0X ↗
- ChEMBLCHEMBL1743062 ↗
Also known as
- 1121b
- cyramza
- cyramza
- cyramza
- cyramza
- cyramza
- imc1121b
- imc 1121b
- imc-1121b
- imc-1121b
- imc-1121b
- imc-1121b
- ramucirumab
- ramucirumab
- ramucirumab
- ramucirumab
- ramucirumab
- ramucirumab
- ramucirumab
- ramucirumab
- ramucirumab
- ramucirumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06675136 | Phase 1 | Oct 17, 2025 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT06996782 | Phase 1/Phase 2 (Phase 2) | Oct 13, 2025 | AstraZeneca |
| NCT07098338 | Phase 2 | Aug 7, 2025 | AstraZeneca, Daiichi Sankyo |
| NCT06616584 | Phase 2/Phase 3 (Phase 3) | Jul 11, 2025 | National Cancer Institute (NCI), Regeneron, SWOG Cancer Research Network |
| NCT06771622 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2025 | FBD Biologics |
| NCT06680622 | Phase 2 | Dec 31, 2024 | Amgen, IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Institut für Klinische Krebsforschung IKF GmbH, Johannes Gutenburg University, Technical University of Munich |
| NCT06564298 | Phase 2 | Aug 31, 2024 | Nanjing Medical University |
| NCT06445972 | Phase 1/Phase 2 (Phase 2) | Aug 7, 2024 | Merck |
| NCT06441019 | Phase 2 | Jul 1, 2024 | Fudan University |
| NCT06203600 | Phase 2/Phase 3 (Phase 3) | Jun 24, 2024 | National Cancer Institute (NCI), SWOG Cancer Research Network |
| NCT06346392 | Phase 3 | Mar 4, 2024 | AstraZeneca |
| NCT06251973 | Phase 2 | Feb 1, 2024 | Memorial Sloan-Kettering Cancer Center |
| NCT06043427 | Phase 2 | Jan 15, 2024 | Canadian Cancer Trials Group, Jazz Pharmaceuticals, University of Toronto |
| NCT06031688 | Phase 2 | Jan 6, 2024 | National Cancer Institute (NCI), SWOG Cancer Research Network |
| NCT06123494 | Phase 3 | Jan 1, 2024 | Hengrui Therapeutics, Inc. |
| NCT06169410 | Phase 4 | Dec 30, 2023 | Xijing Hospital |
| NCT05980000 | Phase 2 | Oct 27, 2023 | Eli Lilly, Washington University in St. Louis |
| NCT06029127 | Phase 2 | Oct 23, 2023 | BeOne Medicines |
| NCT06038578 | Phase 2 | Oct 4, 2023 | Toray Industries, Inc |
| NCT05927857 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2023 | Chang Gung University, China Medical University, Government of Taiwan, Kaohsiung Medical University, National Cheng Kung University, Taipei Veteran General hospital |
Showing 20 of 159 trials
Page 1 / 8
Organizations
Research & Development (100)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 81 | 62 | 4 | 2005 |
| National Cancer Institute (NCI) | Government | 19 | 3 | 3 | 2010 |
| Southwest Oncology Group | Academic/Hospital | 7 | 7 | 2 | 2018 |
| AstraZeneca | For profit | 6 | 3 | 3 | 2016 |
| Merck | For profit | 6 | 1 | 2 | 2014 |
| Washington University in St. Louis | Academic/Hospital | 6 | 5 | 1 | 2017 |
| Bristol-Myers Squibb | For profit | 5 | 2 | 1 | 2018 |
| Hoosier Cancer Research Network | Academic/Hospital | 4 | 3 | 1 | 2016 |
| J. W. Goethe University | Academic/Hospital | 4 | 4 | 2 | 2016 |
| IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest | Academic/Hospital | 3 | 2 | 2 | 2019 |
| Imclone | For profit | 3 | 0 | 2 | 2010 |
| SWOG Cancer Research Network | Academic/Hospital | 3 | 2 | 2 | 2024 |
| University of Texas at Houston | Academic/Hospital | 3 | 2 | 1 | 2015 |
| Celgene | For profit | 2 | 0 | 1 | 2015 |
| Clovis Oncology | For profit | 2 | 0 | 1 | 2019 |
| Cornell University | Academic/Hospital | 2 | 1 | 2 | 2016 |
| Daiichi Sankyo | For profit | 2 | 1 | 2 | 2021 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 2 | 2 | 1 | 2023 |
| National Cancer Center, Japan | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Ono Pharmaceuticals | For profit | 2 | 1 | 2 | 2017 |
100 organizations
Page 1 / 5